Huntington's Disease Mechanistic Pathway
Introduction Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expanded CAG trinucleotide repeat in the [HTT](/genes/htt) gene, which encodes the huntingtin protein. The pathogenic expansion results in a mutant huntingtin protein (mHTT) with an expanded polyglutamine (polyQ) tract that gains toxic functions while losing normal protective activities. This page outlines the key molecular and cellular mechanisms driving HD pathogenesis.
Overview | Property | Value | |----------|-------| | Causative Gene | [HTT](/genes/htt) (Huntingtin) | | Mutation | CAG trinucleotide repeat expansion | | Normal CAG Repeats | ≤26 | | Pathogenic CAG Repeats | ≥36 | | Protein Product | Huntingtin protein (3,144 amino acids) | | Primary Brain Regions Affected | Striatum (caudate, putamen), cerebral cortex | | Key Pathological Features | mHTT aggregates, striatal neuron loss, cortical atrophy |
Molecular Mechanisms
Mutant Huntingtin Toxicity The expanded polyglutamine tract in mutant huntingtin (mHTT) leads to toxic gain-of-function through multiple interconnected mechanisms:
Protein Misfolding and Aggregation
The expanded polyQ tract causes conformational changes and protein misfolding
mHTT forms soluble oligomers and insoluble aggregates in neurons
Aggregates are found in striatum, cortex, and other brain regions[@saudou2016]
Both nuclear and cytoplasmic inclusions contribute to toxicity
...
Huntington's Disease Mechanistic Pathway
Introduction Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expanded CAG trinucleotide repeat in the [HTT](/genes/htt) gene, which encodes the huntingtin protein. The pathogenic expansion results in a mutant huntingtin protein (mHTT) with an expanded polyglutamine (polyQ) tract that gains toxic functions while losing normal protective activities. This page outlines the key molecular and cellular mechanisms driving HD pathogenesis.
Overview | Property | Value | |----------|-------| | Causative Gene | [HTT](/genes/htt) (Huntingtin) | | Mutation | CAG trinucleotide repeat expansion | | Normal CAG Repeats | ≤26 | | Pathogenic CAG Repeats | ≥36 | | Protein Product | Huntingtin protein (3,144 amino acids) | | Primary Brain Regions Affected | Striatum (caudate, putamen), cerebral cortex | | Key Pathological Features | mHTT aggregates, striatal neuron loss, cortical atrophy |
Molecular Mechanisms
Mutant Huntingtin Toxicity The expanded polyglutamine tract in mutant huntingtin (mHTT) leads to toxic gain-of-function through multiple interconnected mechanisms:
Protein Misfolding and Aggregation
The expanded polyQ tract causes conformational changes and protein misfolding
mHTT forms soluble oligomers and insoluble aggregates in neurons
Aggregates are found in striatum, cortex, and other brain regions[@saudou2016]
Both nuclear and cytoplasmic inclusions contribute to toxicity
Loss of Normal Huntingtin Function
Wild-type huntingtin is essential for neuronal survival
Normal HTT regulates neurotrophic factor production (BDNF)
HTT participates in vesicle trafficking and autophagy
The mutation disrupts these essential protective functions[@lands2012]
Transcriptional Dysregulation Mutant huntingtin disrupts gene expression through multiple mechanisms:
Transcription Factor Sequestration
mHTT sequesters transcription factors including REST, NCoR, and p53
REST mislocalization leads to dysregulation of neuronal genes
Histone acetylation defects impair chromatin accessibility[@hunt2011]
DNA Damage and Repair
mHTT impairs DNA repair mechanisms
Accumulation of DNA damage in neurons
Transcriptional programs critical for neuronal function are disrupted
Gene Expression Changes
Downregulation of neurotrophic factors (BDNF)
Loss of neuronal identity markers
Upregulation of inflammatory genes
Mitochondrial Dysfunction Mitochondrial impairment is a central feature of HD pathogenesis:
Energy Metabolism Defects
Reduced complex I, II, and III activity in striatum
Decreased ATP production capacity
Increased sensitivity to metabolic stress[@gu2011]
PGC-1α Dysregulation
Reduced PGC-1α expression and activity
Impaired mitochondrial biogenesis
Defective mitochondrial quality control[@kim2010]
Mitochondrial Dynamics
Altered fission/fusion balance
Increased mitochondrial fragmentation
Impaired mitochondrial transport
Calcium Handling
Dysregulated calcium signaling
Increased sensitivity to excitotoxicity
Impaired mitochondrial calcium uptake
Signaling Pathways
Mermaid diagram (expand to render)
Key Molecular Interactions
mTOR Pathway : Impaired autophagy leads to accumulation of mHTT aggregates
BDNF Signaling : Reduced trophic support contributes to neuronal vulnerability
CREB Signaling : Transcriptional dysfunction affects neuronal survival genes
Calcium Signaling : Excitotoxicity via NMDA receptor overactivation
NF-κB Pathway : Neuroinflammation via microglial activation[@taylor2016]
Cellular Mechanisms
Striatal Medium Spiny Neuron Vulnerability The striatum, particularly medium spiny neurons (MSNs), shows the earliest and most severe degeneration in HD:
MSNs comprise 90% of striatal neurons
D1- and D2-expressing MSNs both affected
Early loss of indirect pathway neurons contributes to chorea
Loss of direct pathway neurons leads to bradykinesia
Cortical Involvement Progressive cortical degeneration accompanies striatal loss:
Layer 3 and 5 pyramidal neurons show vulnerability
Corticostriatal connectivity is disrupted
Contributes to cognitive impairment
Neuroinflammation Microglial activation is prominent throughout HD progression:
Increased TSPO binding on PET imaging
Elevated cytokines in CSF and brain tissue
Contributes to disease progression[@taylor2016]
Genetic Modifiers Recent genetic studies have identified modifiers of HD onset and progression:
| Gene | Modifier Effect | Reference | |------|-----------------|-----------| | MSH3 | Modifies age at onset; DNA mismatch repair | [@sportelli2020] | | FAN1 | DNA repair nuclease; onset modifier | | | RHA | Repeat-binding protein | | | RAN | Translation of Repeat-Containing Proteins | |
Therapeutic Targets | Target | Approach | Development Status | |--------|----------|-------------------| | HTT Gene | ASO gene silencing (Tominersen) | Phase 3 (GENERATION-HD2) | | HTT Gene | AAV RNAi delivery | Preclinical | | Mutant Protein | Aggregation inhibitors | Research | | Transcriptional dysfunction | HDAC inhibitors | Phase 2 | | Mitochondrial function | PGC-1α activators | Research | | Neuroinflammation | Microglial modulation | Research | | BDNF signaling | BDNF mimetics | Research |
Cross-Linked Pages
[HTT Gene](/genes/htt)
[Huntingtin Protein](/proteins/huntingtin-protein)
[Huntington's Disease](/diseases/huntingtons)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
[Neuroinflammation](/mechanisms/neuroinflammation-pathway)
[Transcriptional Dysregulation](/mechanisms/transcriptional-dysregulation)
[Striatal Selective Vulnerability](/mechanisms/striatal-selective-vulnerability-huntingtons)
References
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
[Saudou & Humbert, The Biology of Huntingtin (2016)](https://doi.org/10.1016/j.neuron.2016.02.003)
[Tabrizi et al., Biological and clinical manifestations of HD (2019)](https://doi.org/10.1016/S1474-4422(19)30347-6)
[Lands et al., Huntington's disease: underlying molecular mechanisms (2012)](https://doi.org/10.1007/s00401-012-0989-1)
[Hunt & Ryu, Transcriptional dysregulation in Huntington's disease (2011)](https://doi.org/10.1016/j.tins.2011.06.005)
[Gu et al., Mitochondrial dysfunction in Huntington's disease (2011)](https://doi.org/10.1172/JCI43665)
[Kim et al., Impaired mitochondrial function in Huntington's disease (2010)](https://doi.org/10.1038/nrneurol.2010.60)
[Taylor et al., Neuroinflammation in Huntington's disease (2016)](https://doi.org/10.1038/nrneurol.2016.71)
[Creighton et al., Mutant huntingtin aggregation and cellular toxicity (2020)](https://doi.org/10.3233/JHD-200003)
[Kumar et al., Synaptic dysfunction in Huntington's disease (2020)](https://doi.org/10.1016/j.nbd.2020.104904)
[Sportelli et al., Genetic modifiers of Huntington's disease (2020)](https://doi.org/10.3233/JHD-200391)
Show full description